共 5 条
- [2] 2013 ACCF/AHA Guideline for the Management of Heart Failure[J] . Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff.Circulation . 2013 (16)
- [3] Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)[J] . John J. V. McMurray,Milton Packer,Akshay S. Desai,Jim Gong,Martin P. Lefkowitz,Adel R. Rizkala,Jean Rouleau,Victor C. Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile
- [4] Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)[J] . Jessie Gu,Adele Noe,Priya Chandra,Suliman Al-Fayoumi,Monica Ligueros-Saylan,Ramesh Sarangapani,Suzanne Maahs,Gary Ksander,Dean F. Rigel,Arco Y. Jeng,Tsu-Han Lin,Weiyi Zheng,William P. Dole.Journal of Clinical Pharmacology . 2010 (4)
- [5] Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure [J]. LANCET, 1998, 351 (9116): : 1657 - 1658